A comparative study of quality of life, functional and bone outcomes in osteogenesis imperfecta with bisphosphonate therapy initiated in childhood or adulthood | |
Feehan, Andrew G1,2; Zacharin, Margaret R1,2,3; Lim, Angelina S1,4; Simm, Peter J1,2,3 | |
刊名 | Bone
![]() |
2018-08 | |
卷号 | 113页码:137-143 |
ISSN号 | 1873-2763 |
DOI | 10.1016/j.bone.2018.05.021 |
文献子类 | Article |
英文摘要 | Bisphosphonates have been used for treatment of bone fragility disorders for over 25 years to increase bone mineral density (BMD). Anecdotally, bisphosphonate-treated Osteogenesis Imperfecta (OI) has a different trajectory to the natural history of untreated OI in terms of fracture incidence, quality of life and physical function, with minimal published evidence to support this clinical observation. This study describes functional outcomes of a cohort of adults with OI, stratified according to severity and treated with intravenous bisphosphonates as children. Reported outcomes included fracture incidence before and after puberty, mobility and BMD outcomes of this cohort. The cohort was compared to adults with OI who were never treated as children. All participants completed four questionnaires: a study specific questionnaire addressing fracture and treatment history, WHOQOL-BREF (quality of life), SF-36 (musculoskeletal function) and IPAQ (physical activity), and medical records were reviewed. Fifty-two adults with OI (80% response rate) completed the questionnaires; 33 of whom were treated with bisphosphonates in childhood. The childhood treated cohort had higher lumbar spine BMD than the adult treated cohort (z-score - 0.4 at mean age 21.3 years versus -2.1 at mean age 40.9 years; p = 0.003). Pre-pubertal fracture incidence was reduced for all severities of OI in the childhood treated cohort (less severe OI, p = 0.01; more severe OI, p < 0.001), but post-pubertal fracture incidence was higher for less severe OI (p < 0.001). In less severe OI, childhood treated individuals had higher levels of physical activity (p = 0.004) and physical functioning (p = 0.01) than adult treated individuals. Incidence of scoliosis was not different between cohorts. There were no differences in quality of life scores between the two cohorts. Improvements in BMD do not appear to influence the prevalence of scoliosis. Results suggest that treatment with bisphosphonates at an earlier age improves physical activity, particularly in less severe forms of OI but may not alter quality of life. |
语种 | 英语 |
内容类型 | 期刊论文 |
源URL | [http://119.78.100.183/handle/2S10ELR8/266830] ![]() |
专题 | 中国科学院上海药物研究所 |
通讯作者 | Zacharin, Margaret R; Lim, Angelina S; Simm, Peter J |
作者单位 | 1.Hormone Research, Murdoch Childrens Research Institute, Royal Children's Hospital, 50 Flemington Rd, Parkville, 3052, Victoria, Australia; 2.Department of Paediatrics, University of Melbourne, Parkville 3052, Victoria, Australia; 3.Department of Endocrinology, Royal Children's Hospital, 50 Flemington Rd, Parkville, 3052, Victoria, Australia; 4.Centre for Medicine Use and Safety, Monash University, Parkville, 3052, Victoria, Australia |
推荐引用方式 GB/T 7714 | Feehan, Andrew G,Zacharin, Margaret R,Lim, Angelina S,et al. A comparative study of quality of life, functional and bone outcomes in osteogenesis imperfecta with bisphosphonate therapy initiated in childhood or adulthood[J]. Bone,2018,113:137-143. |
APA | Feehan, Andrew G,Zacharin, Margaret R,Lim, Angelina S,&Simm, Peter J.(2018).A comparative study of quality of life, functional and bone outcomes in osteogenesis imperfecta with bisphosphonate therapy initiated in childhood or adulthood.Bone,113,137-143. |
MLA | Feehan, Andrew G,et al."A comparative study of quality of life, functional and bone outcomes in osteogenesis imperfecta with bisphosphonate therapy initiated in childhood or adulthood".Bone 113(2018):137-143. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论